Table 4

Crude odds ratio and risk ratio of early anti-TNF therapy for sustained steroid-free mild or inactive disease without treatment intensification at one year by paediatric Crohn’s disease risk groups.

SubgroupOR95% CIp-valueRR95% CIp-value
Mild/inactive disease at diagnosis3.861.27–11.720.022.910.92–9.110.07
Moderate/severe disease at diagnosis7.223.45–15.13<0.0015.502.51–12.05<0.001
No POPO4.631.03–20.870.0463.410.54–21.70.19
Any POPO6.663.48–12.72<0.0015.052.45–10.43<0.001
SubgroupOR95% CIp-valueRR95% CIp-value
Mild/inactive disease at diagnosis3.861.27–11.720.022.910.92–9.110.07
Moderate/severe disease at diagnosis7.223.45–15.13<0.0015.502.51–12.05<0.001
No POPO4.631.03–20.870.0463.410.54–21.70.19
Any POPO6.663.48–12.72<0.0015.052.45–10.43<0.001

TNF, tumour necrosis factor; OR, odds ratio; CI, confidence interval; RR, relative risk; POPO, predictor of poor outcome.

Table 4

Crude odds ratio and risk ratio of early anti-TNF therapy for sustained steroid-free mild or inactive disease without treatment intensification at one year by paediatric Crohn’s disease risk groups.

SubgroupOR95% CIp-valueRR95% CIp-value
Mild/inactive disease at diagnosis3.861.27–11.720.022.910.92–9.110.07
Moderate/severe disease at diagnosis7.223.45–15.13<0.0015.502.51–12.05<0.001
No POPO4.631.03–20.870.0463.410.54–21.70.19
Any POPO6.663.48–12.72<0.0015.052.45–10.43<0.001
SubgroupOR95% CIp-valueRR95% CIp-value
Mild/inactive disease at diagnosis3.861.27–11.720.022.910.92–9.110.07
Moderate/severe disease at diagnosis7.223.45–15.13<0.0015.502.51–12.05<0.001
No POPO4.631.03–20.870.0463.410.54–21.70.19
Any POPO6.663.48–12.72<0.0015.052.45–10.43<0.001

TNF, tumour necrosis factor; OR, odds ratio; CI, confidence interval; RR, relative risk; POPO, predictor of poor outcome.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close